Members
| Location: | Dorval, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.thallion.com |
| Contact: |
Allan Mandelzys (amandelzys@thallion.com) 1 514 9403600 |
| Ownership: | Public - Toronto Stock Exchange (TSX): TLN.TO |
| Description: | Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology, with a current emphasis on developing a treatment for Shigatoxin-producing E. coli (STEC) bacterial infections. |
| Location: | Montreal, Quebec |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.jblgroup.ca |
| Contact: |
Bernard Lachapelle (info@jbl.ca) 1 514 866 1551 |
| Description: | JBL Group is a multi-faceted consulting firm, specializing in Health Policy, Government Affairs and Access for the health care industry in Canada and abroad. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.pangaea-consultants.com |
| Contact: |
Joe Knott (info@pangaea-consultants.com) 1 416 5163524 |
| Description: | The Pangaea Group has extensive consulting & outsourcing experience in the Canadian Pharma market place. We add a broader, multi-faceted perspective that produces greater insight and results. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.therapurebio.com |
| Contact: |
Nicholas Green (ceo@therapurebio.com) 1 905 2866200 |
| Description: | Therapure Biopharma Inc. is a Contract Development and Manufacturing Organization (CDMO) committed to the development, manufacture, purification, and packaging of high-quality biological therapeutics. The company offers: • GMP Biologic Manufacturing • Aseptic Fill/Finish and Lyophilization • Analytical Development and Testing • Technology Transfer and Development • Support Services The company develop and manufacture therapeutics for biopharmaceutical companies of all sizes and provide clients and partners with customized solutions for the development and manufacture of complex biological products, leveraging flexible, modern cGMP manufacturing facility, extensive quality systems and the dedication of highly experienced staff. |
| Location: | Montréal, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.thrasos.com |
| Contact: |
(info@thrasos.com) 1 514 940 2714 |
| Description: | Thrasos TherapeuticsTM is a private, clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. Their lead product THR-184 is a peptide formulated for intravenous delivery. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.torys.com |
| Contact: |
Oriana Cheung (ocheung@torys.com) 1 416 8650040 |
| Description: | Torys LLP is a business law firm with 300 lawyers in its offices in New York and Toronto. Torys’ life sciences practice has expertise in corporate/commercial and intellectual property aspects of life sciences projects on both sides of the U.S.- Canada border. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.transitiontherapeutics.com |
| Contact: |
Tony Cruz (tcruz@transitiontherapeutics.com) 1 416 2607770 |
| Ownership: | Public - Toronto Stock Exchange (TSX): TTH.TO |
| Description: | Transition is a biopharmaceutical company developing novel therapeutics for disease indications with large markets. Their lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.trilliumtherapeutics.com |
| Contact: |
Niclas Stiernholm (niclas@trilliumtherapeutics.com) 1 416 5950627 |
| Description: | Trillium Therapeutics Inc. (TTI) is a privately-owned, Toronto-based biopharmaceutical company with two main areas of focus: cytoprotection and immune regulation. The Company's cytoprotection programs are based upon a recombinant form of heparin-binding epidermal growth factor-like growth factor (HB-EGF). In the immune regulation space, Trillium is developing a suite of innovate immunomodulatory products that are capable of either suppressing the immune system, for the treatment of autoimmunity, inflammation and hematopoietic stem cell transplantation (HSCT), or activating the immune system, for the treatment of cancer. Specifically, Trillium’s portfolio includes: • Two cytoprotective programs around TTI-1612, a recombinant growth factor that is being developed as a treatment for interstitial cystitis (IC) and for the prevention of necrotizing enterocolitis (NEC). Trillium recently commenced a single ascending dose trial in IC patients. • Three pre-clinical cancer programs, including a fully human CD200-specific monoclonal antibody, a Fc fusion protein CD47 antagonist, and a SIRPa agonist. |
| Location: | Oakville, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.ucb.com |
| Contact: |
(MedicalInformationCAN@ucb.com) 1 905 2875129 |
| Ownership: | Subsidiary - : |
| Description: | UCB is a global biopharma focused on severe diseases with operations in about 40 countries. UCB Canada Inc. was officially incorporated in 2006 with the objective of bringing new-generation therapies to the Canadian market for auto-immune and central nervous system diseases. |
| Location: | Guelph, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.uoguelph.ca |
| Contact: |
Alastair Summerlee (president@uoguelph.ca) 1 519 8244120 |
| Description: | The University of Guelph is a medium-sized university. University has over 90 majors in 13 degree programs and 63 Open Learning/Distance Education Opportunities. |
| Location: | Winnipeg, Manitoba |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | umanitoba.ca |
| Contact: |
(public_affairs@umanitoba.ca) 1 204 474 8880 |
| Description: | The University of Manitoba is the province’s most comprehensive and only research-intensive post-secondary educational institution. It is Western Canada’s first university and was founded in 1877. In a typical year, the university has an enrolment of 24,542 undergraduate students and 3,021 graduate students. The university offers 82 degrees, 51 at the undergraduate level. Most academic units offer graduate studies programs leading to master’s or doctoral degrees. |
| Location: | Charlottetown, Prince Edward Island |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.upei.ca |
| Contact: |
H. Wade MacLauchlan (president@upei.ca) 1 902 6284353 |
| Description: | UPEI is involved in international development work, overseas research, and actively promotes awareness and involvement in the international community. |
| Location: | Waterloo, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | uwaterloo.ca/ |
| Contact: |
David Johnston (gsoffice@uwaterloo.ca) 1 519 888 4567 |
| Description: | University of Waterloo is a leading public academic institution in Canada. |
| Location: | Victoria, British Columbia |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.uvic.ca/industry |
| Contact: |
(industry@uvic.ca) 1 250 7216500 |
| Description: | UVic Industry Partnerships is the industry liaison office for the University of Victoria and provides a comprehensive suite of services to facilitate industry engagement with researchers and commercialize intellectual property. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.vido.org |
| Contact: |
Paul Hodgson (info@vido.org) 1 306 966 7465 |
| Description: | VIDO-InterVac is a research organization located on the campus of the University of Saskatchewan in Saskatoon, Saskatchewan. Their mission is to be a pre-eminent research institute investigating the pathogenesis of infectious diseases and the development of effective therapeutic and prophylactic methods to control infectious diseases of humans and animals. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.valeantcanada.com |
| Contact: |
Serge Verreault (bd.canada@valeant.com) 1 905 2863000 |
| Ownership: | Public - New York Stock Exchange (NYSE): VRX |
| Description: | Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients' lives. Valeant is focused in the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Australia, Switzerland and Central Europe. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.vbivaccines.com |
| Contact: |
(info@VBIvaccines.com) 1 613 7494200 |
| Ownership: | Subsidiary - : |
| Description: | VBI is engaged in the development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. Their lead product in development is a Thermostable IM flu vaccine that could be customized for the different needs of key population segments - pediatric, adult and geriatric in both established and emerging markets. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.vidatherapeutics.com |
| Contact: |
Alistair Duncan (info@vidatherapeutics.com) 1 778 373 0916 |
| Description: | viDA is a preclinical biotechnology company pursuing the development of first-in-class drugs for the treatment of several inflammatory and age-related conditions of the skin, respiratory, musculoskeletal, cardiovascular, and neurological systems. The company's platform is based on recently identified, specifically extracellular, pathological roles of a family of granule secreted enzymes called Granzymes. The company's focus is specifically on extracellular Granzyme B (GzmB) and its role in a range of disease states involving inflammation and tissue damage. GzmB actively participates in degradation of key components of the body’s extracellular matrix, which acts as a scaffold for cell binding and provides essential structural integrity for proper function of tissues and organs. The company's aim is to show the clinical potential of inhibiting extracellular GzmB in the area of dermatology first, before attempting clinical development in other indications. |
| Location: | Victoria, British Columbia |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.viforpharma.com |
| Contact: |
Christina Hertig (media@galenica.com) 1 250 744 2488 |
| Ownership: | Subsidiary - SIX Swiss Exchange: GALN |
| Description: | Vifor Pharma is a fully integrated specialty pharma company of the Galenica Group. It is based on two main pillars: the business units Rx (prescription products) and Consumer Healthcare (OTC products). |
| Location: | Exton, Pennsylvania |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.viropharma.com |
| Contact: |
Clayton Fletcher (clayton.fletcher@viropharma.com) 1 610 4587300 |
| Ownership: | Public - NASDAQ: VPHM |
| Description: | ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs. Company's product CINRYZE® (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder |
| Location: | Mississauga, Manitoba |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.viventia.com |
| Contact: |
Glen MacDonald (bd@viventia.com) 1 905 3622973 |
| Description: | Viventia is a privately-held biopharmaceutical company developing and advancing the next generation of human monoclonal antibodies (MAbs) for use in oncology. Viventia’s lead MAb products, Vicinium™ and Proxinium™ are used for the treatment of non-muscle invasive bladder cancer and squamous cell cancer of the head & neck. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Supplier & Engineering |
| Website: | www.vwrcanlab.com/ |
| Contact: |
(vwrmx@vwr.com) 1 800 932 5000 |
| Ownership: | Subsidiary - : |
| Description: | VWR International is a worldwide distributor of scientific equipment, supplies, chemicals and furniture, serving the industrial, government, life science, clinical, education, electronics and pharmaceutical markets. |
| Location: | London, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.researchpark.ca |
| Contact: |
Terry King (info@researchpark.ca) 1 519 8585198 |
| Description: | Western Research Park has served as a strong link between academics and commerce, and a key contributor to the movement of an idea or a discovery from concept to the marketplace. Western University Research Park, established in 1989, is one of Canada’s leading science and technology parks and is affiliated with one of Canada’s largest universities. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.wexpharma.com |
| Contact: |
Walter Korz (busdev@wexpharma.com) 1 604 683 8880 |
| Ownership: | Subsidiary - : |
| Description: | WEX Pharmaceuticals Inc. is a pharmaceutical company dedicated to the discovery of new therapeutic agents for the treatment of moderate to severe pain. WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Tetrodotoxin (TTX), a highly selective sodium channel blocker, which is in Phase III clinical development for the treatment of cancer-related pain. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.woodbridgegroup.com |
| Contact: |
Hamdy Khalil (hamdy_khalil@woodbridgegroup.com) 1 905 896 3626 |
